Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869.

Article  PubMed  PubMed Central  Google Scholar 

Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

Article  CAS  PubMed  Google Scholar 

Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 WHO classification of tumours of the breast. Histopathology. 2020;77:181–5.

Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer. 2021;125:164–75.

Article  PubMed  PubMed Central  Google Scholar 

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929–43.

CAS  PubMed  PubMed Central  Google Scholar 

Chen R, Goodison S, Sun Y. Molecular profiles of matched primary and metastatic tumor samples support a linear evolutionary model of breast cancer. Cancer Res. 2020;80:170–4.

Article  CAS  PubMed  Google Scholar 

Wang Y, Armstrong SA. Cancer: inappropriate expression of stem cell programs? Cell Stem Cell. 2008;2:297–9.

Article  PubMed  Google Scholar 

Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149:994–1007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12:381–94.

Article  CAS  PubMed  Google Scholar 

Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, et al. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nat Commun. 2020;11:385.

Article  PubMed  PubMed Central  Google Scholar 

Falato C, Schettini F, Pascual T, Brasó-Maristany F, Prat A. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treat Rev. 2023;112:102496.

Article  CAS  PubMed  Google Scholar 

Zhang R, Tu J, Liu S. Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity. Semin Cancer Biol. 2022;82:11–25.

Article  CAS  PubMed  Google Scholar 

Burr R, Gilles C, Thompson EW, Maheswaran S. Epithelial-mesenchymal plasticity in circulating tumor cells, the precursors of metastasis. Adv Exp Med Biol. 2020;1220:11–34.

Article  CAS  PubMed  Google Scholar 

Mao X, Jin F. The exosome and breast cancer cell plasticity. Onco Targets Ther. 2019;12:9817–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang QA, Scherer PE. Remodeling of murine mammary adipose tissue during pregnancy, lactation, and involution. J Mammary Gland Biol Neoplasia. 2019;24:207–12.

Article  PubMed  PubMed Central  Google Scholar 

Kong D, Hughes CJ, Ford HL. Cellular plasticity in breast cancer progression and therapy. Front Mol Biosci. 2020;7:72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol. 2021;321:C343–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13:227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, et al. FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer. Clin Cancer Res. 2019;25:6443–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10:1–14.

Article  CAS  Google Scholar 

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, et al. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9:eaai7993.

Article  PubMed  PubMed Central  Google Scholar 

Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, et al. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers. 2020;12:2713.

Mieczkowski K, Kitowska K, Braun M, Galikowska-Bogut B, Gorska-Arcisz M, Piasecka D, et al. FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer. Mol Oncol. 2022;16:2823–42.

Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget. 2016;7:86011–25.

Article  PubMed  PubMed Central  Google Scholar 

Turczyk L, Kitowska K, Mieszkowska M, Mieczkowski K, Czaplinska D, Piasecka D, et al. FGFR2-driven signaling counteracts tamoxifen effect on ERalpha-positive breast cancer cells. Neoplasia. 2017;19:791–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9:R23.

Article  PubMed  PubMed Central  Google Scholar 

Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21:100–7.

Article  CAS  PubMed  Google Scholar 

Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin Cancer Res. 2017;23:4323–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaibar M, Novillo A, Romero-Lorca A, Malón D, Antón B, Moreno A, et al. FGFR1 Amplification and response to neoadjuvant Anti-HER2 treatment in early HER2-positive breast cancer. Pharmaceutics. 2022;14:242.

Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: a promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther. 2020;214:107590.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kostrzewa M, Müller U. Genomic structure and complete sequence of the human FGFR4 gene. Mamm Genome. 1998;9:131–5.

Article  CAS  PubMed  Google Scholar 

Holzmann K, Grunt T, Heinzle C, Sampl S, Steinhoff H, Reichmann N, et al. Alternative splicing of fibroblast growth factor receptor IgIII Loops in cancer. J Nucleic Acids. 2012;2012:950508.

Article  PubMed  Google Scholar 

Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Investig. 2020;130:4871–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, et al. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013;73:5926–35.

Article  CAS  PubMed  Google Scholar 

Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013;14:166–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–4.

Article  CAS  PubMed  Google Scholar 

Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687–95.

Article